Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gland Pharma, a Fosun Subsidiary, Plans $650 Million IPO in India

publication date: Jul 15, 2020

Gland Pharma, an Indian generic drug maker majority owned by Shanghai Fosun Pharma, has filed to raise at least $650 million in an IPO on the Bombay and India National Stock Exchanges. In 2017, Fosun acquired a 74% stake in Gland for $1.1 billion. Gland makes complex generic injectible drugs that are sold largely in the US and EU. For India, Gland will be the first China controlled company listed on their domestic markets. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here